1. Metra, M. & Teerlink, J. R. Heart failure. Lancet 390, 1981–1995 (2017).
2. The FANTOM Consortium. The transcriptional landscape of the mammalian genome. Science 309, 1559–1563 (2005).
3. Guttman, M. et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458, 223–227 (2009).
4. van Heesch, S. et al. The translational landscape of the human heart. Cell 178, 242–260 (2019).
5. Gupta, M. P. Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure. J. Mol. Cell. Cardiol. 43, 388–403 (2007).
6. McKinsey, T. A. & Olson, E. N. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J. Clin. Invest. 115, 538–546 (2005).
7. Weber, J. et al. Structural basis of nucleic-acid recognition and double-strand unwinding by the essential neuronal protein Pur-alpha. Elife 5, 213 (2016).
8. Khalili, K. et al. Puralpha is essential for postnatal brain development and developmentally coupled cellular proliferation as revealed by genetic inactivation in the mouse. Mol. Cell. Biol. 23, 6857–6875 (2003).
9. Gupta, M., Zak, R., Libermann, T. A. & Gupta, M. P. Tissue-restricted expression of the cardiac alpha-myosin heavy chain gene is controlled by a downstream repressor element containing a palindrome of two ets-binding sites. Mol. Cell. Biol. 18, 7243–7258 (1998).
10. Gupta, M., Sueblinvong, V., Raman, J., Jeevanandam, V. & Gupta, M. P. Single-stranded DNA-binding proteins PURalpha and PURbeta bind to a purine-rich negative regulatory element of the alpha-myosin heavy chain gene and control transcriptional and translational regulation of the gene expression. Implications in the repression of alpha-myosin heavy chain during heart failure. J. Biol. Chem. 278, 44935–44948 (2003).
11. Lin, M. F., Jungreis, I. & Kellis, M. PhyloCSF: a comparative genomics method to distinguish protein coding and non-coding regions. Bioinformatics 27, i275–i282 (2011).
12. Nelson, T. J., Balza, R., Xiao, Q. & Misra, R. P. SRF-dependent gene expression in isolated cardiomyocytes: regulation of genes involved in cardiac hypertrophy. J. Mol. Cell. Cardiol. 39, 479–489 (2005).
13. Bär, C., Chatterjee, S. & Thum, T. Long noncoding RNAs in cardiovascular pathology, diagnosis, and therapy. Circulation 134, 1484–1499 (2016).
14. Han, P. et al. A long noncoding RNA protects the heart from pathological hypertrophy. Nature 514, 102–106 (2014).
15. Viereck, J. et al. Long noncoding RNA Chast promotes cardiac remodeling. Sci. Transl. Med. 8, 326ra22 (2016).
16. Wang, Z. et al. The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nat. Med. 22, 1131–1139 (2016).
17. Wang, K. et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ. Res. 114, 1377–1388 (2014).
18. Johnson, E. M., Daniel, D. C. & Gordon, J. The pur protein family: genetic and structural features in development and disease. J. Cell. Physiol. 228, 930–937 (2013).
19. Latos, P. A. et al. Airn transcriptional overlap, but not its lncRNA products, induces imprinted Igf2r silencing. Science 338, 1469–1472 (2012).
20. Bassett, A. R. et al. Considerations when investigating lncRNA function in vivo. Elife 3, e03058 (2014).
21. Yang, K.-C. et al. Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support. Circulation 129, 1009–1021 (2014).
22. Ono, K., Kuwabara, Y., Horie, T. & Kimura, T. Long non-coding RNAs as key regulators of cardiovascular diseases. Circ. J. 82, 1231–1236 (2018).
23. Quattrocelli, M. et al. Long-term miR-669a therapy alleviates chronic dilated cardiomyopathy in dystrophic mice. J. Am. Heart Assoc. 2, e000284 (2013).
24. Michael, J. V. et al. Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth. Blood 130, 567–580 (2017).
25. Rockman, H. A. et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc. Natl Acad. Sci. USA 88, 8277–8281 (1991).
26. Nishiga, M. et al. MicroRNA-33 controls adaptive fibrotic response in the remodeling heart by preserving lipid raft cholesterol. Circ. Res. 120, 835–847 (2017).
27. Horie, T. et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc. Natl Acad. Sci. USA 107, 17321–17326 (2010).
28. Sowa, N. et al. MicroRNA 26b encoded by the intron of small CTD phosphatase (SCP) 1 has an antagonistic effect on its host gene. J. Cell. Biochem. 113, 3455–3465 (2012).
29. Kuwabara, Y. et al. MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway. Circ. Res. 116, 279–288 (2015).
30. Hatani, T., Miki, K. & Yoshida, Y. Induction of human induced pluripotent stem cells to cardiomyocytes using embryoid bodies. Methods Mol. Biol. 79–92, 2018 (1816).
31. Nagao, K. et al. Myocardial expression level of neural cell adhesion molecule correlates with reduced left ventricular function in human cardiomyopathy. Circulation: Heart Fail. 7, 351–358 (2014).
32. Kuwabara, Y. et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ. Cardiovasc. Genet. 4, 446–454 (2011).
33. Matsui, S. et al. Neuronal SIRT1 regulates macronutrient-based diet selection through FGF21 and oxytocin signalling in mice. Nat. Commun. 9, 4604 (2018).
34. Kawaguchi, R. & Kiryu, H. Parallel computation of genome-scale RNA secondary structure to detect structural constraints on human genome. BMC Bioinforma. 17, 203 (2016).